Dr. Robert T. Neff, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Wright State University Boonshoft School of Medicine (2011)
- Years since graduation
- 15
- In the NPI registry since
- 2011
- Medicare patients seen, 2024
- 112
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2011Medical school: Wright State University Boonshoft School of Medicine
- 2011Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
OH license 35.126214 · KY license 51464
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
- Good Samaritan Hospital Cincinnati, OH
- Mercy Health St Ritas Medical Center Lima, OH
Medical groups
- Osu Gyn and Ob Consultants LLC (70 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 112
- Services billed
- 291
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 104 | 43 |
| Established patient office or other outpatient visit, 40-54 minutes | 75 | 33 |
| Established patient office or other outpatient visit, 20-29 minutes | 53 | 43 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 27 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Oxycodone Hcl Other prescribers in Hilliard, OH | 24 |
| Lynparza (olaparib) | 23 |
| Prochlorperazine Maleate Other prescribers in Hilliard, OH | 23 |
| Eliquis (apixaban) Other prescribers in Hilliard, OH | 13 |
| Dexamethasone Other prescribers in Hilliard, OH | 13 |
| Tramadol Hcl Other prescribers in Hilliard, OH | 12 |
| Megestrol Acetate Other prescribers in Hilliard, OH | 11 |
| Ondansetron Hcl Other prescribers in Hilliard, OH | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $18.26 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $18.26 |
|---|
| Food and Beverage | $18.26 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $95,123 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator's Choice (IC) in Patients With Platinum Resistant Ovarian Cancer
Genmab U.S., Inc. - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)
Aadi Bioscience, Inc. · Completed · NCT05103358 - A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
Daiichi Sankyo Inc. · Active, not recruiting · NCT04707248
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.